ARQ 621 是一种变构和选择性 Eg5 有丝分裂运动蛋白抑制剂，具有抗肿瘤活性。

ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1.

ARQ 621 demonstrates anti-tumor activity against a wide range of human cancer cell lines in vitro, including colon, lung, endometrial, bladder, and hematologic cancer cell lines, with significantly less cytotoxicity against hematopoietic cells. [1]

ARQ 621, as a novel clinical stage drug candidate, inhibits a number of xenografts grown in athymic mice, such as pancreatic, breast, prostate, and ovarian carcinomas with no hematological changes. Furthermore, for ARQ 621, there is no envidence of bone marrow toxicity in pre-clinical mouse efficacy models or safety studies in rats and dogs. [1]

1095253-39-6

C28H24Cl2FN5O2

552.43

H2O:<1 mgml
Ethanol:93 mg/mL (168.3 mM)
DMSO:93 mg/mL (168.3 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years